204 related articles for article (PubMed ID: 17023229)
21. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
22. Controlled-release carvedilol.
Carter NJ; Keating GM
Am J Cardiovasc Drugs; 2008; 8(4):271-82. PubMed ID: 18690761
[No Abstract] [Full Text] [Related]
23. Carvedilol.
Frishman WH
Indian Heart J; 1999; 51(3):325-32. PubMed ID: 10624077
[No Abstract] [Full Text] [Related]
24. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.
Stoschitzky K; Stoschitzky G; Brussee H; Bonelli C; Dobnig H
Cardiology; 2006; 106(4):199-206. PubMed ID: 16679760
[TBL] [Abstract][Full Text] [Related]
25. Long-term oral carvedilol in chronic heart failure.
Di Lenarda A; Sabbadini G; Moretti M; Sinagra G
Expert Opin Pharmacother; 2004 Jun; 5(6):1359-72. PubMed ID: 15163280
[TBL] [Abstract][Full Text] [Related]
26. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.
Kim YH; Choi HY; Noh YH; Lee SH; Lim HS; Kim C; Bae KS
Drug Des Devel Ther; 2015; 9():2911-8. PubMed ID: 26089641
[TBL] [Abstract][Full Text] [Related]
27. [Carvedilol].
Antepohl W; Herzig S; Böhm M
Dtsch Med Wochenschr; 1997 Jun; 122(25-26):833-4. PubMed ID: 9244672
[No Abstract] [Full Text] [Related]
28. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
29. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans.
de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG
Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256
[TBL] [Abstract][Full Text] [Related]
30. Carvedilol: the new role of beta blockers in congestive heart failure.
Vanderhoff BT; Ruppel HM; Amsterdam PB
Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960
[TBL] [Abstract][Full Text] [Related]
31. Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load.
De Vecchis R; Pucciarelli G; Setaro A; Nocerino L
Minerva Cardioangiol; 2000 Nov; 48(11):393-410. PubMed ID: 11214431
[TBL] [Abstract][Full Text] [Related]
32. Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?
Sanderson JE; Leung LY; Chan SK; Yip GW; Fung JW; Yu CM
Eur J Heart Fail; 2005 Aug; 7(5):874-7. PubMed ID: 16043407
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
[TBL] [Abstract][Full Text] [Related]
34. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
DasGupta P; Broadhurst P; Lahiri A
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
[TBL] [Abstract][Full Text] [Related]
35. Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure.
Rector TS; Anand IS; Nelson DB; Ensrud KE
J Am Geriatr Soc; 2008 Jun; 56(6):1021-7. PubMed ID: 18384583
[TBL] [Abstract][Full Text] [Related]
36. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
McTavish D; Campoli-Richards D; Sorkin EM
Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
[TBL] [Abstract][Full Text] [Related]
37. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Bullinga JR; Alharethi R; Schram MS; Bristow MR; Gilbert EM
J Card Fail; 2005 Dec; 11(9):693-9. PubMed ID: 16360965
[TBL] [Abstract][Full Text] [Related]
38. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure.
Vittorio TJ; Zolty R; Kasper ME; Khandwalla RM; Hirsh DS; Tseng CH; Jorde UP; Ahuja K
J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):51-7. PubMed ID: 18287590
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Takayanagi R; Fujito K; Kimura K; Yamada Y
Biol Pharm Bull; 2017; 40(6):837-843. PubMed ID: 28566627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
